Streetbeat News

Earnings

KD

STLA

Kyndryl Holdings, Inc. (NYSE:KD) has expanded its multi-year deal with Stellantis N.V. (NYSE:STLA) to manage and operate select essential business operations including networking, data center support, and local IT services in Europe, North America, and South America. This extension builds on the agreement from February 2023 aimed at modernizing Stellantis' IT infrastructure. Kyndryl also reported Q3 adjusted EPS of $(0.05), beating consensus, and sales of $3.94 billion, surpassing estimates. The company revised its FY24 outlook, expecting at least $150 million in adjusted pretax income and a revenue decline of (6%) to (7%) in constant currency.

Portfolio Pulse from Lekha Gupta

March 04, 2024 | 12:50 pm

CME

CME Group announced its February 2024 market statistics, revealing an average daily volume of 29.6 million contracts, marking a 5% increase year-over-year and achieving the second highest average daily volume for February on record.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 12:41 pm

EB

MANU

ROKU

The article highlights three tech and telecom stocks - Eventbrite, Inc. (EB), Roku, Inc. (ROKU), and Manchester United plc (MANU) - that are considered oversold in the communication services sector, presenting a potential buying opportunity. It uses the Relative Strength Index (RSI) as a momentum indicator, with an RSI below 30 suggesting oversold conditions. Eventbrite reported strong Q4 revenue growth, Roku showed a 14% year-over-year increase in Q4 revenue, and Manchester United announced a successful minority investment by Sir Jim Ratcliffe.

Portfolio Pulse from Avi Kapoor

March 04, 2024 | 12:41 pm

JSPR

Jasper Therapeutics announced significant progress in its clinical trials and financial achievements. The company completed a $50 million stock offering, extending its cash runway through Q3 2025. It received regulatory clearance in the US and EU for the BEACON and SPOTLIGHT studies of briquilimab in CSU and CIndU patients, respectively, and initiated a Phase 1 trial for briquilimab in myelodysplastic syndromes. Initial data from these studies are expected in 2024. Additionally, Jasper presented promising preclinical data at the AAAAI 2024 Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 12:39 pm

JSPR

Jasper Therapeutics reported its fiscal year 2023 financial results, including a net loss of $64.5 million, or $6.18 per share, and a cash balance of $86.9 million. Research and development expenses were $51.8 million, while general and administrative expenses totaled $17.1 million.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 12:35 pm

AVDL

Avadel Pharmaceuticals' shares surged following the announcement of their Q4 revenue results, which exceeded market expectations.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 12:34 pm

INDP

Indaptus Therapeutics announced positive results from the second cohort of its Phase 1 trial for Decoy 20, leading to the initiation of a multi-dose cohort. The data from the single dose cohort is expected to be published at a scientific conference in 2024.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 12:33 pm

NVDA

U.S. markets closed higher on Friday, led by Nvidia and a tech rally, despite a drop in ISM manufacturing PMI and consumer sentiment. Asian markets were mixed, with Japan's Nikkei reaching a record high. European markets and U.S. futures saw declines. Commodities showed mixed performance with crude oil slightly down and natural gas up. Nvidia's performance stands out due to the growing demand for artificial intelligence.

Portfolio Pulse from Akanksha Bakshi

March 04, 2024 | 12:29 pm

ENTG

Entegris has updated its Q1 FY2024 guidance, now expecting an adjusted EBITDA margin of approximately 27%-28%, an increase from the previously forecasted range of 26.5%-27.5%.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 12:18 pm

ENTG

Entegris has updated its Q1 FY2024 adjusted EPS guidance to $0.59-$0.64, slightly below its prior guidance of $0.60-$0.65 and in line with the consensus estimate of $0.62.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 12:17 pm